Galectin Therapeutics (GALT) Dividends payables (2010 - 2025)
Galectin Therapeutics (GALT) posted quarterly Dividends payables of $63000.0 for Q4 2025, little changed year-over-year from $63000.0 in Q4 2024, and little changed quarter-over-quarter from $63000.0 in Q2 2025.
Galectin Therapeutics (GALT) Dividends payables (2010 - 2025) Analysis & Trends
Galectin Therapeutics' Dividends payables history runs 16 years deep, the most recent figure standing at $63000.0 for Q4 2025.
- In Q4 2025, Dividends payables changed 0.0% year-over-year to $63000.0; the TTM figure through Dec 2025 stood at $63000.0 (changed 0.0% YoY), while the FY2025 annual figure was $63000.0, changed 0.0% from the prior year.
- Dividends payables for Q4 2025 stood at $63000.0, roughly flat from $63000.0 in the prior quarter.
- The five-year high for Dividends payables was $65000.0 in Q2 2021, with the low at $63000.0 in Q4 2023.
- The 5-year median for Dividends payables is $63500.0 (2022), against an average of $63700.0.
- The sharpest annual moves came in 2021 and 2023: Dividends payables changed 0.0% in 2021, then slipped 1.56% in 2023.
- Galectin Therapeutics' Dividends payables stood at $65000.0 in 2021, then declined by 1.54% to $64000.0 in 2022, then retreated by 1.56% to $63000.0 in 2023, then changed by 0.0% to $63000.0 in 2024, then changed by 0.0% to $63000.0 in 2025.
- Business Quant data shows GALT's Dividends payables at $63000.0 in Q4 2025, $63000.0 in Q2 2025, and $63000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Galectin Therapeutics | 226.55 Mn | 226.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 63,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Dec 31, 2024 | 63,000.00 |
| Jun 30, 2024 | 63,000.00 |
| Dec 31, 2023 | 63,000.00 |
| Jun 30, 2023 | 64,000.00 |
| Dec 31, 2022 | 64,000.00 |
| Jun 30, 2022 | 64,000.00 |
| Dec 31, 2021 | 65,000.00 |
| Jun 30, 2021 | 65,000.00 |
| Dec 31, 2020 | 65,000.00 |
| Jun 30, 2020 | 66,000.00 |
| Dec 31, 2019 | 66,000.00 |
| Jun 30, 2019 | 66,000.00 |
| Dec 31, 2018 | 299,000.00 |
| Jun 30, 2018 | 67,000.00 |
| Dec 31, 2017 | 68,000.00 |
| Jun 30, 2017 | 68,000.00 |
| Dec 31, 2016 | 68,000.00 |
| Jun 30, 2016 | 68,000.00 |